ARF4

Across TCGA pan-cancer cohorts, ARF4 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARF4’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARF4 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARF4 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where ARF4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARF4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	+0.586	<.001	9	view →
LSCC	Male	All	+0.254	<.001	6	view →
PDAC	Female	II,III,IV	−0.727	<.001	5	view →
COAD	Female	All	+0.183	<.001	5	view →
HNSC	Male	All	−0.216	.032	3	view →
CCRCC	All	IV	+0.252	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARF4–LUAD

Open the LUAD breakdown →